News

In May 2014, the companies have agreed on the development of MGD010, and the four new research programs are in addition to that product. Each of the four

Abilify Maintena is an atypical antipsychotic indicated for the treatment of schizophrenia; efficacy was demonstrated in a placebo-controlled, randomized-withdrawal maintenance trial in patients with schizophrenia and additional support

"With ImmunoClin’s track record in assisting biotech, pharma and food companies as well as public institutions in pharmaceutical and nutraceutical development projects, we are excited to initiate this

Based on a planned interim analysis of the co-primary endpoint, the objective response rate (ORR) was 32% (95% CI = 24, 41) in the Opdivo arm (n=120) and

Research to be funded by the Bill & Melinda Gates Foundation The study will be led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS

Through the extended agreement, Kamada secured $26 million in additional revenues of Glassia, the Company’s proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic

Vitavis CEO Tim Tigner said Pruvin supports healthy metabolism resulting in numerous significant benefits to users. "Pruvin supports healthy metabolism resulting in numerous significant benefits to users," Tigner

The agreement also includes an additional contingent consideration of about $350m based on achievement of certain sales milestones The acquisition will give AMAG access to Lumara’s Makena, the

As part of the deal, Perrigo will receive an upfront payment in addition to multiple development-related milestone payments and royalties on any future sales derived from the portfolio.